Analytical Data
-
Gene name
VEGF-D
- Application
-
Alternative Names
Vascular endothelial growth factor D; VEGFD; c-Fos-induced growth factor
-
Species
Cynomolgus
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
G7Q297
-
Expression Region
F93-S201
-
Protein Length
Partial
-
Molecular Weight
27-30 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular endothelial growth factor D (VEGF-D) is a member of the VEGF family, which plays a critical role in lymphangiogenesis and angiogenesis, processes essential for normal physiological functions as well as in pathological conditions such as cancer, lymphedema, and inflammatory diseases. Research on VEGF-D has gained momentum due to its significant role in the formation of lymphatic vessels and its potential implications in tumor metastasis and lymphatic system disorders. Unlike other members of the VEGF family, VEGF-D specifically acts on lymphatic endothelial cells, promoting their proliferation and migration. Variations in VEGF-D expression have been associated with various diseases, making it a potential biomarker for disease progression. Additionally, therapeutic interventions targeting VEGF-D may provide novel strategies for treating conditions linked to its dysregulation. The recombinant protein version of VEGF-D has been studied as a tool for both basic research and potential therapeutic applications, exploring its function in promoting lymphatic vessel growth in animal models and assessing its safety and efficacy in clinical settings. As our understanding of VEGF-D's mechanistic roles deepens, it opens avenues for innovative treatments in cancer therapy and regenerative medicine, harnessing its properties to enhance tissue repair and modulate immune responses. This growing body of research emphasizes the importance of VEGF-D in both health and disease, highlighting its potential as a target for future therapeutic development and clinical applications.
